Mckesson Corporation (MCK) Valuation

The valuation assessment reveals a stark contradiction. The GoodMoat Target of $13,906.70 implies an intrinsic value over 15 times the current price of $879.75. According to the framework's DCF-based Margin of Safety (MoS) bands, this would represent a MoS well over 40%, classifying it as 'Deeply Undervalued.' However, this target is an extreme outlier and suggests a potential data error or model calibration issue, as it is inconsistent with the company's reported financial metrics. A P/E of 25x is high for a medical distributor, a typically low-margin business, especially when the profit margin is only 1.1%. This combination suggests the market is pricing the stock for significant future profit expansion that is not yet evident in current margins. The 4.8% Free Cash Flow Yield is modest and does not compensate for the high earnings multiple. When comparing the P/E to the sector and considering the company's thin profitability, the stock appears expensive. The valuation case is unfavourable as the current price does not align with the fundamental quality indicated by the low margins, and the provided target price lacks credibility for practical analysis.